Adipotide (FTPP) 5mg
Pro-Apoptotic Fat Cell Peptide for Targeted Adipose Reduction
Adipotide (FTPP) is a peptidomimetic that selectively targets vasculature feeding white adipose tissue, inducing apoptosis in fat cell blood vessels to cause selective fat tissue reduction. Showed 11% body fat loss in obese primates.
Pro-Apoptotic Fat Cell Peptide for Targeted Adipose Reduction
Adipotide combines a PDGF receptor-binding targeting sequence with a cell death-inducing KLAKLAK sequence to specifically destroy blood vessels supplying white adipose tissue, causing selective adipocyte death without affecting other tissues.
As one of the most studied compounds in the metabolic & fat loss research space, Adipotide has attracted sustained scientific interest across Targeted fat loss research, Adipose vasculature biology, Novel obesity mechanism studies. Peer-reviewed evidence indicates that 11% body fat reduction in 28 days in primates, which has positioned Adipotide as a reference standard for researchers exploring targeted fat loss research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Adipotide Documented Benefits: 3 Documented Mechanisms
Targeted Adipose Apoptosis
Selectively destroys vasculature feeding fat tissue, causing localized adipocyte death.
Dramatic Fat Reduction
Achieved 11% body fat reduction in 28 days in obese primate studies.
Unique Mechanism
Vascular targeting mechanism completely distinct from GLP-1 or lipase-based approaches.
How Adipotide Works: Molecular Mechanism & Pathway
Bifunctional peptidomimetic with PDGFR-targeting sequence directing KLAKLAK pro-apoptotic sequence to adipose vasculature, inducing mitochondrial disruption in fat tissue blood vessels.
The 3 primary research pathways identified for Adipotide — Targeted Adipose Apoptosis, Dramatic Fat Reduction, Unique Mechanism — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that selective adipose vasculature targeting, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Adipotide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Adipotide is routinely studied alongside Retatrutide and AOD9604 in metabolic & fat loss-focused compound panels. Researchers investigating targeted fat loss research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that distinct from all other fat loss mechanisms has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Adipotide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- 11% body fat reduction in 28 days in primates
- Selective adipose vasculature targeting
- Distinct from all other fat loss mechanisms
Ideal For
- Targeted fat loss research
- Adipose vasculature biology
- Novel obesity mechanism studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Adipotide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
11% body fat reduction in 28 days in primates
Selective adipose vasculature targeting
Distinct from all other fat loss mechanisms
Third-Party Verified Every Batch
Each vial of Adipotide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
